| Literature DB >> 32545579 |
Magdalena Mackiewicz-Milewska1, Małgorzata Cisowska-Adamiak1, Danuta Rość2, Iwona Głowacka-Mrotek1, Iwona Świątkiewicz3,4.
Abstract
BACKGROUND: Patients with spinal cord injury (SCI) exhibit hemostasis disorders. This study aims at assessing the effects of a 4-week rehabilitation program on hemostasis disorders in patients with SCI.Entities:
Keywords: exercises; hemostasis; rehabilitation; spinal cord injury; venous thrombosis
Year: 2020 PMID: 32545579 PMCID: PMC7355642 DOI: 10.3390/jcm9061836
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Study group characteristics: number of patients (N) with specific symptoms.
| Symptom or Incident |
|
|---|---|
| Tetraplegia | 34 (43.6%) |
| Flaccid paraplegia | 18 (23.1%) |
| Spastic paraplegia | 26 (33.3%) |
| Cervical spine injury | 37 (44.4%) |
| Thoracic spine injury | 33 (42.3%) |
| Lumbosacral spine injury | 8 (10.3%) |
| AIS A | 34 (43.6%) |
| AIS B | 30 (36.5%) |
| AIS C | 14 (17.9%) |
| Decubitus ulcers | 11 (14.1%) |
| Urinary tract infection | 26 (33.3%) |
| Heterotopic ossifications | 13 (16.6%) |
| Administration of LMWH | 53 (67.9%) |
| Deep vein thrombosis | 7 (9.0%) |
| Superficial vein thrombosis of the lower limbs | 4 (5.1%) |
| Pulmonary embolism | 0 |
Data represent the number of patients (N) including the percentage of total number (%). Abbreviations: AIS—American Spinal Injury Association Impairment Scale; AIS A—impairment is complete according to AIS; AIS B and C—impairment is incomplete according to AIS; LMWH—low-molecular-weight heparin.
Plasma concentrations of TF, TFPI, and TAT complex in the study group vs. the control group before four-week rehabilitation program.
| Study Group | Control Group | ||||
|---|---|---|---|---|---|
| Parameter | Median | Q25/Q75 | Median | Q25/Q75 | |
| TF (pg/mL) | 453.84 | 327.30/567.66 | 128.26 | 90.44/183.40 | 0.000 |
| TFPI (ng/mL) | 103.26 | 59.36/131.50 | 59.90 | 43.30/96.76 | 0.001 |
| TAT (ng/mL) | 8.75 | 5.29/17.54 | 2.20 | 1.98/3.36 | 0.000 |
Abbreviations: TAT—thrombin–antithrombin complex; TF—tissue factor; TFPI—tissue factor pathway inhibitor; Q25—lower quartile; Q75—upper quartile.
Parameters of hemostasis in the study subjects before and after a four-week rehabilitation program.
| Test ( | Before Rehabilitation | After Rehabilitation | ||||
|---|---|---|---|---|---|---|
| Parameter | Units | Median | Q25/Q75 | Median | Q25/Q75 | |
| PLT count | g/L | 252.00 | 204.00/352.00 | 249.00 | 211.00/317.00 | 0.116 |
| TF | pg/mL | 453.84 | 327.30/567.66 | 459.76 | 348.20/546.84 | 0.371 |
| TFPI | ng/mL | 103.26 | 59.36/131.50 | 92.34 | 52.84/132.04 | 0.075 |
| AT | % | 101.95 | 94.80/112.00 | 101.05 | 91.40/106.70 | 0.071 |
| TAT | ng/mL | 8.75 | 5.29/17.54 | 6.70 | 4.50/10.88 | 0.48 |
| D-dimer | ng/mL | 1249.50 | 600.00/2540.00 | 903.50 | 430.00/1743/00 | 0.001 |
Abbreviations: AT—antithrombin activity; PLT—platelet; TAT—thrombin–antithrombin complex; TF—tissue factor; TFPI—tissue factor pathway inhibitor; Q25—lower quartile; Q75—upper quartile.
Parameters of hemostasis before and after a four-week rehabilitation program in patients from group I (three weeks to three months after injury).
| Test ( | Before Rehabilitation | After Rehabilitation | ||||
|---|---|---|---|---|---|---|
| Parameter | Units | Median | Q25/Q75 | Median | Q25/Q75 | |
| PLT count | g/L | 262.0 | 242.0/352.0 | 255.0 | 218.0/348.0 | 0.180 |
| TF | pg/mL | 482.1 | 338.9/572.6 | 492.2 | 366.6/582.4 | 0.447 |
| TFPI | ng/mL | 90.5 | 52.8/155.9 | 93.3 | 47.7/139.9 | 0.301 |
| AT | % | 102.5 | 97.4/114.9 | 100.2 | 91.1/105.0 | 0.009 |
| TAT | ng/mL | 10.3 | 5.9/18.9 | 7.5 | 5.8/12.6 | 0.326 |
| D-dimer | ng/mL | 2387.5 | 1250.0/5190.0 | 1252.0 | 580.0/2240.0 | 0.000 |
Abbreviations: AT—antithrombin activity; TAT—thrombin–antithrombin complex; TF—tissue factor; TFPI—tissue factor pathway inhibitor; Q25—lower quartile; Q75—upper quartile.
Parameters of hemostasis before and after a four-week rehabilitation program in patients from group II (three months to six months after injury).
| Test ( | Before Rehabilitation | After Rehabilitation | ||||
|---|---|---|---|---|---|---|
| Parameter | Units | Median | Q25/Q75 | Median | Q25/Q75 | |
| PLT count | g/L | 322.00 | 229.00/363.00 | 262.50 | 216.00/322.00 | 0.042 |
| TF | pg/mL | 453.84 | 337.59/617.60 | 451.31 | 333.12/506.50 | 0.485 |
| TFPI | ng/mL | 111.34 | 72.20/143.44 | 88.32 | 60.96/139.70 | 0.022 |
| AT | % | 97.65 | 90.30/111.00 | 99.10 | 87.00/107.80 | 0.126 |
| TAT | ng/mL | 10.40 | 7.18/23.48 | 9.66 | 4.50/15.22 | 0.906 |
| D-dimer | ng/mL | 1033.50 | 515.00/1800.00 | 935.50 | 430.00/1475.00 | 0.733 |
Abbreviations: AT—antithrombin activity; TAT—thrombin–antithrombin complex; TF—tissue factor; TFPI—tissue factor pathway inhibitor; Q25—lower quartile; Q75—upper quartile.
Parameters of hemostasis before and after a four-week rehabilitation program in patients from group III (more than six months after injury).
| Test ( | Before Rehabilitation | After Rehabilitation | ||||
|---|---|---|---|---|---|---|
| Parameter | Units | Median | Q25/Q75 | Median | Q25/Q75 | |
| PLT count | g/L | 205.50 | 181.00/265.00 | 221.00 | 204.00/262.00 | 0.372 |
| TF | ng/mL | 388.90 | 290.25/532.81 | 442.09 | 357.50/498.14 | 0.050 |
| TFPI | ng/mL | 93.75 | 59.36/118.12 | 104.46 | 58.36/126.60 | 0.808 |
| AT | % | 102.55 | 94.00/109.20 | 104.05 | 100.50/112.00 | 0.095 |
| TAT | ng/mL | 5.40 | 3.65/11.52 | 5.15 | 3.06/6.26 | 0.091 |
| D-dimer | ng/mL | 522.00 | 284.00/1057.00 | 420.00 | 262.00/711.00 | 0.768 |
Abbreviations: AT—antithrombin activity; TAT—thrombin–antithrombin complex; TF—tissue factor; TFPI—tissue factor pathway inhibitor; Q25—lower quartile; Q75—upper quartile.